SLITRK3

Summary

SLITRK3 (SLIT and NTRK like family member 3, HGNC:23501) is a protein-coding gene on chromosome 3q26.1, encoding SLIT and NTRK-like protein 3 (O94933). Suppresses neurite outgrowth.

This gene encodes a member of the Slitrk family of structurally related transmembrane proteins that are involved in controlling neurite outgrowth. The encoded protein contains two leucine-rich repeat (LRR) domains and a C-terminal domain that is partially similar to Trk neurotrophin receptor protein. Enhanced expression of this gene was found in tissue from several different types of tumors. Alternative splicing results in multiple transcript variants, all encoding the same protein.

Source: NCBI Gene 22865 — RefSeq curated summary.

At a glance

• Gene–disease (curated): epilepsy (Limited, GenCC) — +1 more curated relationship
• GWAS associations: 3
• Clinical variants (ClinVar): 113 total — 1 pathogenic
• MANE Select transcript: NM_001318810

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23501
Approved symbol	SLITRK3
Name	SLIT and NTRK like family member 3
Location	3q26.1
Locus type	gene with protein product
Status	Approved
Aliases	KIAA0848
Ensembl gene	ENSG00000121871
Ensembl biotype	protein_coding
OMIM	609679
Entrez	22865

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 7 protein_coding

ENST00000241274, ENST00000475390, ENST00000497724, ENST00000925264, ENST00000925265, ENST00000925266, ENST00000925267

RefSeq mRNA: 3 — MANE Select: NM_001318810 NM_001318810, NM_001318811, NM_014926

CCDS: CCDS3197

Canonical transcript exons

ENST00000475390 — 2 exons

Exon	Start	End
ENSE00001837903	165186720	165190851
ENSE00001953036	165195580	165196384

Expression profiles

Bgee: expression breadth ubiquitous, 151 present calls, max score 83.56.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 1.1191 / max 133.7300, expressed in 171 samples.

FANTOM5 promoters (10 alternative TSS)

Promoter ID	TPM avg	Samples expressed
45431	0.3267	94
45432	0.1667	70
45430	0.1544	72
45428	0.0930	52
45433	0.0889	57
45425	0.0841	41
203012	0.0580	42
45426	0.0551	30
45427	0.0512	32
45429	0.0411	28

Top tissues by expression

277 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left uterine tube	UBERON:0001303	83.56	gold quality
middle temporal gyrus	UBERON:0002771	82.75	gold quality
prefrontal cortex	UBERON:0000451	78.70	gold quality
Brodmann (1909) area 46	UBERON:0006483	78.30	gold quality
primary visual cortex	UBERON:0002436	77.77	gold quality
lower esophagus muscularis layer	UBERON:0035833	77.70	gold quality
lower esophagus	UBERON:0013473	77.62	gold quality
Brodmann (1909) area 23	UBERON:0013554	76.90	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	74.84	gold quality
frontal cortex	UBERON:0001870	74.74	gold quality
superior frontal gyrus	UBERON:0002661	74.62	gold quality
postcentral gyrus	UBERON:0002581	74.61	gold quality
neocortex	UBERON:0001950	74.20	gold quality
Brodmann (1909) area 9	UBERON:0013540	74.07	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	74.01	gold quality
cerebral cortex	UBERON:0000956	73.49	gold quality
right frontal lobe	UBERON:0002810	72.92	gold quality
occipital lobe	UBERON:0002021	72.73	gold quality
caudate nucleus	UBERON:0001873	72.50	gold quality
cingulate cortex	UBERON:0003027	72.50	gold quality
telencephalon	UBERON:0001893	72.42	gold quality
nucleus accumbens	UBERON:0001882	72.35	gold quality
anterior cingulate cortex	UBERON:0009835	72.31	gold quality
Ammon’s horn	UBERON:0001954	72.18	gold quality
orbitofrontal cortex	UBERON:0004167	72.11	gold quality
parietal lobe	UBERON:0001872	71.67	gold quality
cerebellar hemisphere	UBERON:0002245	71.62	gold quality
cerebellar cortex	UBERON:0002129	71.61	gold quality
entorhinal cortex	UBERON:0002728	71.50	gold quality
endothelial cell	CL:0000115	71.47	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	3.43

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

102 targeting SLITRK3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-3134	100.00	66.43	777
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-574-5P	100.00	66.01	989
HSA-MIR-511-3P	99.99	68.85	1467
HSA-MIR-8082	99.95	67.27	1170
HSA-MIR-6835-3P	99.93	70.49	2904
HSA-MIR-515-5P	99.92	69.82	2343
HSA-MIR-519E-5P	99.92	69.62	2358
HSA-MIR-10523-5P	99.91	69.22	2038
HSA-MIR-106A-5P	99.90	73.94	2683
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-17-5P	99.89	73.83	2665
HSA-MIR-106B-5P	99.88	74.72	2795
HSA-MIR-20A-5P	99.88	74.76	2769
HSA-MIR-20B-5P	99.88	74.01	2621
HSA-MIR-519D-3P	99.88	73.97	2607
HSA-MIR-93-5P	99.88	73.98	2606
HSA-MIR-30A-3P	99.87	69.74	2928
HSA-MIR-30D-3P	99.87	69.92	2917
HSA-MIR-30E-3P	99.87	69.68	2942
HSA-MIR-548AZ-5P	99.83	69.94	3230
HSA-MIR-548T-5P	99.83	69.91	3220
HSA-MIR-1323	99.83	69.89	2471
HSA-MIR-4420	99.82	70.08	1624
HSA-MIR-4307	99.82	70.45	3374

Literature-anchored findings (GeneRIF, showing 2)

• SLITRK3 expression is a highly significant predictor of gastrointestinal stromal tumor recurrence and metastasis. (PMID:26217092)
• SLITRK2, an X-linked modifier of the age at onset in C9orf72 frontotemporal lobar degeneration. (PMID:34687211)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	slitrk3a	ENSDARG00000078123
mus_musculus	Slitrk3	ENSMUSG00000048304
rattus_norvegicus	Slitrk3	ENSRNOG00000009821

Paralogs (25): LRFN3 (ENSG00000126243), LRFN1 (ENSG00000128011), SLIT2 (ENSG00000145147), LRFN2 (ENSG00000156564), LRRC38 (ENSG00000162494), SLITRK5 (ENSG00000165300), LRFN5 (ENSG00000165379), LRTM2 (ENSG00000166159), LINGO1 (ENSG00000169783), LRRN2 (ENSG00000170382), LRRN3 (ENSG00000173114), LRFN4 (ENSG00000173621), LINGO2 (ENSG00000174482), LRRN1 (ENSG00000175928), SLITRK1 (ENSG00000178235), GP5 (ENSG00000178732), SLITRK4 (ENSG00000179542), LRRC55 (ENSG00000183908), SLIT3 (ENSG00000184347), SLITRK6 (ENSG00000184564), SLITRK2 (ENSG00000185985), LRRC70 (ENSG00000186105), SLIT1 (ENSG00000187122), TLR9 (ENSG00000239732), TPBGL (ENSG00000261594)

Protein

Protein identifiers

SLIT and NTRK-like protein 3 — O94933 (reviewed: O94933)

All UniProt accessions (2): C9K0R4, O94933

UniProt curated annotations — full annotation on UniProt →

Function. Suppresses neurite outgrowth.

Subcellular location. Membrane.

Tissue specificity. Expressed in the occipital lobe of the cerebral cortex of the brain. Expressed at higher levels in some astrocytic brain tumors such as astrocytomas, oligodendrogliomas, glioblastomas, gangliogliomas and primitive neuroectodermal tumors.

Similarity. Belongs to the SLITRK family.

RefSeq proteins (3): NP_001305739, NP_001305740, NP_055741 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000483	Cys-rich_flank_reg_C	Domain
IPR001611	Leu-rich_rpt	Repeat
IPR003591	Leu-rich_rpt_typical-subtyp	Repeat
IPR032675	LRR_dom_sf	Homologous_superfamily

Pfam: PF13855

UniProt features (29 total): repeat 12, domain 3, region of interest 3, topological domain 2, compositionally biased region 2, glycosylation site 2, signal peptide 1, chain 1, sequence variant 1, sequence conflict 1, transmembrane region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O94933-F1	64.70	0.24

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (2): 68, 596

Function

Pathways and Gene Ontology

Reactome pathways

8 pathways

ID	Pathway
R-HSA-388844	Receptor-type tyrosine-protein phosphatases
R-HSA-9013423	RAC3 GTPase cycle
R-HSA-112316	Neuronal System
R-HSA-162582	Signal Transduction
R-HSA-194315	Signaling by Rho GTPases
R-HSA-6794362	Protein-protein interactions at synapses
R-HSA-9012999	RHO GTPase cycle
R-HSA-9716542	Signaling by Rho GTPases, Miro GTPases and RHOBTB3

MSigDB gene sets: 181 (showing top): AGGAAGC_MIR5163P, BENPORATH_ES_WITH_H3K27ME3, GOBP_SYNAPSE_ASSEMBLY, TGCACTT_MIR519C_MIR519B_MIR519A, TTTGTAG_MIR520D, GOBP_POSITIVE_REGULATION_OF_SYNAPSE_ASSEMBLY, GOCC_CELL_SURFACE, GOBP_NEUROGENESIS, GOBP_REGULATION_OF_CELL_JUNCTION_ASSEMBLY, ATGCAGT_MIR217, GOBP_REGULATION_OF_NERVOUS_SYSTEM_DEVELOPMENT, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, GGGTGGRR_PAX4_03, GOBP_POSITIVE_REGULATION_OF_NERVOUS_SYSTEM_DEVELOPMENT, chr3q26

GO Biological Process (9): axonogenesis (GO:0007409), synaptic transmission, GABAergic (GO:0051932), positive regulation of synapse assembly (GO:0051965), terminal button organization (GO:0072553), neurotransmitter-gated ion channel clustering (GO:0072578), gephyrin clustering involved in postsynaptic density assembly (GO:0097116), synaptic membrane adhesion (GO:0099560), regulation of presynapse assembly (GO:1905606), postsynaptic density assembly (GO:0097107)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (7): plasma membrane (GO:0005886), cell surface (GO:0009986), postsynaptic density membrane (GO:0098839), GABA-ergic synapse (GO:0098982), postsynaptic specialization membrane (GO:0099634), membrane (GO:0016020), postsynaptic membrane (GO:0045211)

Reactome top-level categories

Rollup of top-6 pathways:

Category	Pathways
Protein-protein interactions at synapses	1
RHO GTPase cycle	1
Signaling by Rho GTPases, Miro GTPases and RHOBTB3	1
Neuronal System	1
Signaling by Rho GTPases	1
Signal Transduction	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of synapse assembly	2
synapse organization	2
cellular anatomical structure	2
postsynaptic membrane	2
synaptic membrane	2
cell morphogenesis involved in neuron differentiation	1
neuron projection morphogenesis	1
axon development	1
chemical synaptic transmission	1
synapse assembly	1
positive regulation of nervous system development	1
positive regulation of cell junction assembly	1
presynapse organization	1
receptor clustering	1
protein localization to synapse	1
postsynaptic density assembly	1
cell-cell adhesion	1
presynapse assembly	1
regulation of presynapse organization	1
postsynaptic density organization	1
postsynaptic specialization assembly	1
excitatory synapse assembly	1
binding	1
membrane	1
cell periphery	1
postsynaptic density	1
postsynaptic specialization membrane	1
synapse	1
postsynaptic specialization	1
postsynapse	1

Protein interactions and networks

STRING

1858 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLITRK3	PTPRD	P23468	858
SLITRK3	NLGN2	Q8NFZ4	805
SLITRK3	IL1RAPL1	Q9NZN1	715
SLITRK3	PTPRS	Q13332	660
SLITRK3	NTRK1	P04629	588
SLITRK3	NLGN1	Q8N2Q7	546
SLITRK3	NTRK3	Q16288	527
SLITRK3	GPHN	Q9NQX3	501
SLITRK3	NRXN2	Q9P2S2	497
SLITRK3	LRR1	Q96L50	492
SLITRK3	NRXN1	Q9ULB1	468
SLITRK3	PTPRF	P10586	466
SLITRK3	UNC5D	Q6UXZ4	454
SLITRK3	NLGN3	Q9NZ94	450
SLITRK3	BOC	Q9BWV1	423

IntAct

16 interactions, top by confidence:

A	B	Type	Score
SLITRK3	WFS1	psi-mi:“MI:0915”(physical association)	0.560
EGFR	NDUFA4	psi-mi:“MI:0914”(association)	0.530
SLITRK3	H2BC9	psi-mi:“MI:0915”(physical association)	0.400
SLITRK3	H1-2	psi-mi:“MI:0915”(physical association)	0.400
SLITRK3	H3C13	psi-mi:“MI:0915”(physical association)	0.400
SLITRK3	RHBDF2	psi-mi:“MI:0915”(physical association)	0.400
SBSN	SLITRK3	psi-mi:“MI:0915”(physical association)	0.400
CACNA1C	DISP2	psi-mi:“MI:0914”(association)	0.350
HCN1	POTEF	psi-mi:“MI:0914”(association)	0.350
SLITRK3	TCAF2	psi-mi:“MI:0914”(association)	0.350
KCNE3	PIK3R2	psi-mi:“MI:0914”(association)	0.350
PCDHGA7	SDCBP	psi-mi:“MI:0914”(association)	0.350
TRIM54	SLITRK3	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (22): SLITRK3 (Affinity Capture-MS), SLITRK3 (Affinity Capture-RNA), SLITRK3 (Proximity Label-MS), SLITRK3 (Synthetic Lethality), HIST1H1C (Proximity Label-MS), SLITRK3 (Proximity Label-MS), HIST1H2BH (Proximity Label-MS), SLITRK3 (Two-hybrid), ERBB2 (Affinity Capture-MS), SLITRK3 (Affinity Capture-MS), KCNT2 (Affinity Capture-MS), FAM115C (Affinity Capture-MS), ACVR2A (Affinity Capture-MS), VAMP4 (Affinity Capture-MS), ATE1 (Affinity Capture-MS)

ESM2 similar proteins: A1XQX3, A1XQY0, A1XQY3, A2ALI5, A6QLD2, B5X216, D0PRN4, E9PUN2, O35181, O75151, O94933, O94991, P0C7U0, P15379, P23470, P49415, P56975, P58401, P80560, Q05909, Q3SXY7, Q3UH99, Q3V1G4, Q4W8E7, Q58EG3, Q5EGE1, Q5R3F8, Q5R5B8, Q63376, Q63475, Q68BL8, Q68FM6, Q6QD51, Q6ZSJ9, Q76KF0, Q80Z10, Q810B7, Q810B9, Q8AXP2, Q8C8T7

Diamond homologs: E9Q7T7, G5EFX6, O02678, O15335, O46390, O46403, O55226, O70210, O94933, O94991, P14770, P21809, P21810, P28653, P47853, P83503, Q27972, Q5RAC4, Q6NUI6, Q6RKD8, Q7Z2Q7, Q810B7, Q810B9, Q810C0, Q810C1, Q8C031, Q8C110, Q91009, Q96PX8, Q9GKQ6, Q9H156, Q9HCJ2, Q9NZU1, B1H234, Q5R6T0, Q8BGT1, Q9NZU0, Q7M6Z0, Q80WD1, Q810B8

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

113 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	106
Likely benign	3
Benign	1

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
930212	NM_001318810.2(SLITRK3):c.1816G>T (p.Glu606Ter)	Pathogenic

SpliceAI

287 predictions. Top by Δscore:

Variant	Effect	Δscore
3:165190847:CAAAA:C	acceptor_gain	1.0000
3:165190852:C:CC	acceptor_gain	0.9900
3:165192715:TGAG:T	donor_gain	0.9900
3:165190848:AAAA:A	acceptor_gain	0.9800
3:165190849:AAA:A	acceptor_gain	0.9800
3:165190850:AA:A	acceptor_gain	0.9800
3:165190851:ACTG:A	acceptor_loss	0.9800
3:165190852:C:CA	acceptor_loss	0.9800
3:165190853:T:G	acceptor_loss	0.9800
3:165192723:G:A	donor_gain	0.9600
3:165192566:CG:C	acceptor_gain	0.9500
3:165193555:TGG:T	donor_gain	0.9400
3:165190859:A:T	acceptor_gain	0.9200
3:165192567:G:C	acceptor_gain	0.9200
3:165190854:G:C	acceptor_loss	0.9100
3:165195264:TTC:T	donor_gain	0.9000
3:165195265:TCT:T	donor_gain	0.9000
3:165195681:AG:A	donor_gain	0.9000
3:165195577:TA:T	donor_loss	0.8900
3:165195578:ACC:A	donor_loss	0.8900
3:165195579:C:A	donor_loss	0.8900
3:165190858:C:CT	acceptor_gain	0.8800
3:165195582:A:AC	donor_gain	0.8700
3:165192712:G:C	donor_gain	0.8600
3:165195580:C:G	donor_loss	0.8600
3:165195676:A:AC	donor_gain	0.8400
3:165195677:C:CC	donor_gain	0.8400
3:165195527:A:AC	donor_gain	0.8300
3:165195528:C:CC	donor_gain	0.8300
3:165195760:C:CT	donor_gain	0.8300

AlphaMissense

6394 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:165189139:C:A	W564C	1.000
3:165189139:C:G	W564C	1.000
3:165189141:A:G	W564R	1.000
3:165189141:A:T	W564R	1.000
3:165189220:G:C	N537K	1.000
3:165189220:G:T	N537K	1.000
3:165189289:G:C	N514K	1.000
3:165189289:G:T	N514K	1.000
3:165189433:G:C	N466K	1.000
3:165189433:G:T	N466K	1.000
3:165189449:A:G	L461P	1.000
3:165189505:A:C	N442K	1.000
3:165189505:A:T	N442K	1.000
3:165189530:A:C	L434W	1.000
3:165189577:A:C	N418K	1.000
3:165189577:A:T	N418K	1.000
3:165189593:A:G	L413P	1.000
3:165189655:G:C	C392W	1.000
3:165189656:C:G	C392S	1.000
3:165189656:C:T	C392Y	1.000
3:165189657:A:G	C392R	1.000
3:165189657:A:T	C392S	1.000
3:165189662:A:T	V390D	1.000
3:165189694:A:C	C379W	1.000
3:165189695:C:T	C379Y	1.000
3:165189696:A:G	C379R	1.000
3:165189700:A:C	C377W	1.000
3:165189702:A:G	C377R	1.000
3:165189712:G:C	C373W	1.000
3:165189713:C:T	C373Y	1.000

dbSNP variants (sampled 300 via entrez): RS1000180315 (3:165198040 T>G), RS1000283363 (3:165192235 T>A), RS1000592840 (3:165186225 T>G), RS1000752452 (3:165192607 T>G), RS1001206038 (3:165192333 G>C), RS1001296487 (3:165191012 T>C), RS1001643123 (3:165191282 G>T), RS1002067358 (3:165197482 A>G,T), RS1002140772 (3:165197286 G>A), RS1002173973 (3:165189685 G>A), RS1002229992 (3:165195627 A>G,T), RS1002374531 (3:165192084 T>A), RS1002970955 (3:165190873 A>C,G), RS1003034814 (3:165194024 A>C), RS1003127667 (3:165196114 C>A,T)

Disease associations

OMIM: gene MIM:609679 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
epilepsy	Limited	Autosomal dominant
complex neurodevelopmental disorder	Limited	Autosomal recessive

Mondo (3): intellectual disability (MONDO:0001071), epilepsy (MONDO:0005027), complex neurodevelopmental disorder (MONDO:0100038)

Orphanet (1): NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST006585_987	Blood protein levels	4.000000e-19
GCST009391_1199	Metabolite levels	2.000000e-07
GCST009391_46	Metabolite levels	6.000000e-06

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0010456	allantoin measurement
EFO:0010114	citrate measurement

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D004827	Epilepsy	C10.228.140.490
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

25 total (human), top 25 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, affects expression, affects cotreatment	4
Phenylmercuric Acetate	affects cotreatment, increases expression	2
sotorasib	affects cotreatment, increases expression	1
ethyl-p-hydroxybenzoate	increases expression	1
terbufos	increases methylation	1
arsenite	increases methylation	1
ferrous chloride	decreases expression	1
aflatoxin B2	increases methylation	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
trametinib	affects cotreatment, increases expression	1
NVP-BKM120	increases expression, affects cotreatment	1
Sunitinib	increases expression	1
Amiodarone	increases expression	1
Benzo(a)pyrene	affects methylation, decreases methylation, increases methylation	1
Calcitriol	decreases expression, affects cotreatment	1
Cytarabine	decreases expression	1
Fonofos	increases methylation	1
Parathion	increases methylation	1
Rotenone	decreases expression	1
Testosterone	decreases expression, affects cotreatment	1
Asbestos, Serpentine	decreases methylation	1
Asbestos, Crocidolite	increases methylation	1
Antirheumatic Agents	increases expression	1
Okadaic Acid	decreases expression	1

Clinical trials (associated diseases)

497 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00004637	PHASE4	COMPLETED	Double-Blind, Placebo-Controlled Trial of Vitamin E as Add-on Therapy for Children With Epilepsy
NCT00043914	PHASE4	COMPLETED	Measurement Of Serum Levels Of Two Antiepileptic Drugs During Conversion In Patients With Epilepsy
NCT00132223	PHASE4	UNKNOWN	Effects on the Diagnostic Accuracy of Magnetic Imaging Angiographies of the Supra-Aortic Vessels by Three Different Magnetic Resonance Contrast Agents in Patients
NCT00133081	PHASE4	UNKNOWN	Study to Improve the Treatment of Epilepsy (SITE)
NCT00137709	PHASE4	UNKNOWN	Hormone Profiles in Adults With Newly Diagnosed Epilepsy
NCT00154076	PHASE4	COMPLETED	A Multicenter Comparative Trial of Zonisamide and Topiramate as Initial Monotherapy in Untreated Epilepsies
NCT00165828	PHASE4	TERMINATED	Efficacy and Safety of an add-on Treatment With Zonisamide in Adults With Focal Epileptic Seizures With or Without Secondary Generalization
NCT00181116	PHASE4	COMPLETED	Levetiracetam for Benign Rolandic Epilepsy
NCT00207935	PHASE4	COMPLETED	Use of Sustained Release Antiepileptic Medication (Depakote® ER) for Pediatric Epilepsy in a Mental Retardation/Developmental Disorder Population
NCT00215592	PHASE4	COMPLETED	Open Label, Zonegran (Zonisamide) In Partial Onset Seizures
NCT00266604	PHASE4	COMPLETED	A Study to Evaluate the Dosing, Effectiveness and Safety of Topiramate for the Treatment of Epilepsy
NCT00288639	PHASE4	COMPLETED	Lyrica (Pregabalin) Administered as an Add-on Therapy for Partial Seizures (LEADER).
NCT00312676	PHASE4	UNKNOWN	Compare Tolerability of an Overnight Switch to Gradual Switch Between Two Different Forms of Depakote
NCT00323947	PHASE4	COMPLETED	Methylphenidate for Treating Attention Deficit Hyperactivity Disorder in Children With Both ADHD and Epilepsy
NCT00385411	PHASE4	COMPLETED	Study of Valproate in Young Patients Suffering From Epilepsy
NCT00522418	PHASE4	TERMINATED	Study Comparing Best Medical Practice With or Without VNS Therapy in Pharmacoresistant Partial Epilepsy Patients
NCT00537940	PHASE4	COMPLETED	Comparative Study Of Pregabalin And Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures
NCT00552526	PHASE4	UNKNOWN	Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy
NCT00564915	PHASE4	COMPLETED	RCT of the Efficacy of the Ketogenic Diet in the Treatment of Epilepsy
NCT00571155	PHASE4	COMPLETED	Trial of Levetiracetam in Patients With Primary Brain Tumors and Symptomatic Seizures Who Undergo Surgery
NCT00572195	PHASE4	COMPLETED	RNS® System LTT Study
NCT00610532	PHASE4	TERMINATED	Evaluating the Transporter Protein Inhibitor Probenecid In Patients With Epilepsy
NCT00630357	PHASE4	COMPLETED	Trial to Evaluate the Safety and Efficacy of Keppra After Conversion to Mono-therapy in Subjects With Partial Epilepsy
NCT00630630	PHASE4	COMPLETED	Study on Safety and Efficacy of Levetiracetam in the Adjunctive Treatment of Female Subjects With C1 Catamenial Epilepsy
NCT00630968	PHASE4	COMPLETED	S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy
NCT00631150	PHASE4	COMPLETED	A Phase IV-Pharmacovigilance Study of Keppra Greece - S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy
NCT00659958	PHASE4	COMPLETED	ZAGAL Study: Evaluating Effectiveness and Tolerability of Zonisamide as Adjunctive Therapy in Patients With Partial Onset Seizures Treated With Two Antiepileptic Drugs
NCT00713622	PHASE4	COMPLETED	Comparing The Effect On Cognition Of Adjunctive Therapy With Zonisamide Versus Sodium Valproate
NCT00807989	PHASE4	COMPLETED	The Efficacy and Safety of Low Dose Combination of LTG and VPA Compared to CBZ Monotherapy
NCT00832884	PHASE4	COMPLETED	The Safety of Intravenous Lacosamide
NCT00869622	PHASE4	COMPLETED	Antiepileptic Drugs and Osteoporotic Prevention Trial
NCT00896987	PHASE4	COMPLETED	Lamotrigine Cognitive Function Study in Adult Untreated Epilepsies
NCT00952081	PHASE4	COMPLETED	A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients
NCT01118455	PHASE4	TERMINATED	Trial to Assess Vagus Nerve Stimulation Therapy vs. Anti-Epileptic Drug (AED) Treatment in Children With Refractory Seizures
NCT01127165	PHASE4	COMPLETED	Low and High Dose Zonisamide in Children as Monotherapy
NCT01127256	PHASE4	COMPLETED	Comparative Study of Zonisamide and Carbamazepine as an Initial Monotherapy: Efficacy and Safety Evaluation
NCT01140867	PHASE4	COMPLETED	Open-label, Multi-center Trial of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy
NCT01175954	PHASE4	COMPLETED	Cognitive and Behavioral Effects of Lacosamide
NCT01229735	PHASE4	COMPLETED	Levetiracetam Versus Topiramate as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects With Refractory Partial Onset Seizures
NCT01244724	PHASE4	TERMINATED	Lexapro for Major Depression in Patients With Epilepsy